Citius Pharma finalizes 675M oncology unit spinoff - NJBIZ
| CTOR Stock | 0.89 0.03 3.26% |
Slightly above 62% of Citius Oncology,'s investor base is looking to short. The analysis of overall sentiment of trading Citius Oncology, stock suggests that many investors are alarmed at this time. Citius Oncology,'s investing sentiment overview a quick insight into current market opportunities from investing in Citius Oncology,. Many technical investors use Citius Oncology, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Citius Pharma finalizes 675M oncology unit spinoff NJBIZ
Read at news.google.com
 |
Citius Oncology, Fundamental Analysis
We analyze Citius Oncology,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Citius Oncology, is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Citius Oncology, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Citius Oncology, stock to make a market-neutral strategy. Peer analysis of Citius Oncology, could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics with similar companies.
Peers
Citius Oncology, Related Equities
| SOHU | SohuCom | 2.05 | ||||
| GMWKF | Games Workshop | 1.92 | ||||
| NTES | NetEase | 0.67 | ||||
| BC | Brunswick | 0.19 | ||||
| OLED | Universal Display | 0.32 | ||||
| ASO | Academy Sports | 1.44 |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.